GlassScriptPhysician profile
Cherie D Bragg
NPI 1982798807
$7,474.22
in general payments reported to CMS, 2019-2025
39 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $22.16 · 2021: $378 · 2022: $193 · 2023: $1,852 · 2024: $1,759 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,143 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,142.87 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,197.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,150.36 | 2019-2025 | |
| Lilly USA, LLC | $942.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $885.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $644.60 | 2021-2025 | Qulipta, Ubrelvy, Linzess |
| Novo Nordisk INC | $263.12 | 2019-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $259.87 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.36 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $205.93 | 2023-2025 | Rexulti |
| Dexcom, INC. | $198.38 | 2022-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lundbeck LLC | $180.24 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $162.95 | 2021-2025 | |
| Amgen INC. | $124.10 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $115.30 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $94.39 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherie Bragg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.